BridgeBio Pharma (BBIO) Accounts Payables (2018 - 2026)

BridgeBio Pharma has disclosed Accounts Payables across 9 years of filings, most recently posting $29.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $29.1 million, up 5.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.1 million (up 5.57% YoY), and the FY2025 annual result was $36.2 million, up 276.67% from the prior year.
• Accounts Payables came in at $29.1 million for Q1 2026 at BridgeBio Pharma, down from $36.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $36.2 million in Q4 2025 to a low of $3.9 million in Q2 2023.
• The 5-year median for Accounts Payables is $10.7 million (2023), against an average of $14.5 million.
• Across the five-year window, Accounts Payables tumbled 60.62% in 2022 and jumped 482.17% in 2025, its largest moves.
• BridgeBio Pharma's Accounts Payables stood at $11.6 million in 2022, then fell by 7.81% to $10.7 million in 2023, then decreased by 9.73% to $9.6 million in 2024, then soared by 276.67% to $36.2 million in 2025, then declined by 19.79% to $29.1 million in 2026.
• The last three Accounts Payables figures came in at $29.1 million (Q1 2026), $36.2 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.